Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 10/20 | 0.59 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.59 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AHCYL1 | O43865 | 2/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12281130 | 0.83 | PI4KA (0.61) | AHCYPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL864471 | 0.83 | PI4KA (0.61) | AHCYPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL12281072 | 0.78 | AHCY (0.35) | AHCYEZH2PI4KAPI4K2BPI4K2A | |
| SCHEMBL13664039 | 0.78 | AHCY (0.35) | AHCYEZH2PI4KAPI4K2BPI4K2A | |
| 3-Deazaneplanocin A SCHEMBL23683021 | 0.75 | AHCY (1.00) | AHCYEZH2SMN1; SMN2AHCYL1DNMT1 | |
| 3-Deazaneplanocin A SCHEMBL12321313 | 0.75 | AHCY (1.00) | AHCYEZH2SMN1; SMN2AHCYL1DNMT1 | |
| 3-Deazaneplanocin A SCHEMBL1521229 | 0.75 | AHCY (1.00) | AHCYEZH2SMN1; SMN2AHCYL1DNMT1 | |
| 3-Deazaneplanocin A SCHEMBL18256281 | 0.75 | AHCY (1.00) | AHCYEZH2SMN1; SMN2AHCYL1DNMT1 | |
| 3-Deazaneplanocin A SCHEMBL863851 | 0.75 | AHCY (1.00) | AHCYEZH2SMN1; SMN2AHCYL1DNMT1 | |
| 3-Deazaneplanocin A SCHEMBL12280318 | 0.75 | AHCY (1.00) | AHCYEZH2SMN1; SMN2AHCYL1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH | 2011-09-29 | — | — | US | disclosed |
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH | 2011-09-29 | — | — | US | disclosed |
| WO-2010036213-A1 | 3-DEAZANEPLANOCIN DERIVATIVES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | EZH2, SUZ12, DAZAP1 | AHCY 4001/4885EZH2 1/4885PI4KA 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.